Ahzantive Injection, Solution
Product Images NDC 85006-2908

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Ahzantive (NDC 85006-2908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Valorum Biologics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton (Carton Label)

Carton (Carton Label)
FDA Label Image

Vial Label (Vial Label)

Vial Label (Vial Label)
The text provides information about a medication named Ahzantivem Rx, which is aflibercept-mrbb injection used for intravitreal use. It is specified as a single-dose vial that needs to be refrigerated. The text also includes details on the lot and expiration date printing format, manufacturing information, and specifications for label design like font type, size, and color details.*
FDA Label Image

Figure 2 (Ahzantive 02)

Figure 2 (Ahzantive 02)
FDA Label Image

Figure 3 (Ahzantive 03)

Figure 3 (Ahzantive 03)
FDA Label Image

Figure 4a (Ahzantive 04)

Figure 4a (Ahzantive 04)
FDA Label Image

Figure 4b (Ahzantive 05)

Figure 4b (Ahzantive 05)
FDA Label Image

Figure 5 (Ahzantive 06)

Figure 5 (Ahzantive 06)
FDA Label Image

Figure 6 (Ahzantive 07)

Figure 6 (Ahzantive 07)
FDA Label Image

Figure 7a (Ahzantive 08)

Figure 7a (Ahzantive 08)
FDA Label Image

Figure 7b (Ahzantive 09)

Figure 7b (Ahzantive 09)
This text appears to be describing instructions for dosing a solution using a flat plunger edge after removing air bubbles and excess drug. The recommended dose is 0.05 mL.*
FDA Label Image

Figure 8 (Ahzantive 10)

Figure 8 (Ahzantive 10)
This is a table showing the mean change in visual acuity over a period of 96 weeks for two different views (view 1 and view 2) and two different treatments (Aflibercept 2mg every 8 weeks and Ranibizumab 0.5mg every 4 weeks). The visual acuity measurements are provided at different time points in weeks.*
FDA Label Image

Figure 9 (Ahzantive 11)

Figure 9 (Ahzantive 11)
This text appears to contain a mix of characters and does not form a coherent description. The content is not available for evaluation.*
FDA Label Image

Figure 10 (Ahzantive 12)

Figure 10 (Ahzantive 12)
FDA Label Image

Figure 11 (Ahzantive 13)

Figure 11 (Ahzantive 13)
FDA Label Image

Figure 12 (Ahzantive 14)

Figure 12 (Ahzantive 14)
FDA Label Image

Figure 1 (Correct Ahzantive Fig07 3)

Figure 1 (Correct Ahzantive Fig07 3)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.